[HTML][HTML] Omicron variant (B. 1.1. 529) and its sublineages: What do we know so far amid the emergence of recombinant variants of SARS-CoV-2?

M Dhawan, ARA Saied, S Mitra, FA Alhumaydhi… - Biomedicine & …, 2022 - Elsevier
Since the start of the COVID-19 pandemic, numerous variants of SARS-CoV-2 have been
reported worldwide. The advent of variants of concern (VOCs) raises severe concerns amid …

[HTML][HTML] Humoral and Cellular Immune Responses of COVID-19 vaccines against SARS-Cov-2 Omicron variant: A systemic review

Z Chen, Y Zhang, M Wang, MS Islam… - … Journal of Biological …, 2022 - ncbi.nlm.nih.gov
Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has undergone
multiple mutations since its emergence, and its latest variant, Omicron (B. 1.1. 529), is the …

Immunosenescence and inflamm-ageing in COVID-19

MR Zinatizadeh, PK Zarandi, M Ghiasi… - Ageing Research …, 2023 - Elsevier
The destructive effects of coronavirus disease 2019 (COVID-19) on the elderly and people
with cardiovascular disease have been proven. New findings shed light on the role of aging …

Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review

Y Du, L Chen, Y Shi - Human Vaccines & Immunotherapeutics, 2022 - Taylor & Francis
There is a wealth of data suggesting that the effectiveness of existing vaccines against the
Omicron variant, the most mutated SARS-CoV-2 variant to date, has been substantially …

Intranasal delivery of a rationally attenuated SARS-CoV-2 is immunogenic and protective in Syrian hamsters

S Liu, CB Stauft, P Selvaraj, P Chandrasekaran… - Nature …, 2022 - nature.com
Few live attenuated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
vaccines are in pre-clinical or clinical development. We seek to attenuate SARS-CoV-2 …

A bacteriophage-based, highly efficacious, needle-and adjuvant-free, mucosal COVID-19 vaccine

J Zhu, S Jain, J Sha, H Batra, N Ananthaswamy… - MBio, 2022 - Am Soc Microbiol
ABSTRACT The US Food and Drug Administration-authorized mRNA-and adenovirus-
based SARS-CoV-2 vaccines are intramuscularly injected in two doses and effective in …

Updated insights into the T cell-mediated immune response against SARS-CoV-2: a step towards efficient and reliable vaccines

M Dhawan, AA Rabaan, MMA Fawarah, SA Almuthree… - Vaccines, 2023 - mdpi.com
The emergence of novel variants of SARS-CoV-2 and their abilities to evade the immune
response elicited through presently available vaccination makes it essential to recognize the …

Effectiveness of COVID-19 vaccines against SARS-CoV-2 Omicron variant (B. 1.1. 529): a systematic review with meta-analysis and meta-regression

NR Pratama, IA Wafa, DS Budi, H Sutanto… - Vaccines, 2022 - mdpi.com
Vaccine effectiveness (VE) and the urgency of booster vaccination against SARS-CoV-2
Omicron variant need evaluation. A systematic search was conducted from 1–6 April, 2022 …

A tabulated summary of the evidence on humoral and cellular responses to the SARS-CoV-2 Omicron VOC, as well as vaccine efficacy against this variant.

SO Minka, FH Minka - Immunology Letters, 2022 - Elsevier
Summary Introduction SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is
the virus responsible for COVID-19. It is one of the most mutating virus in the world. These …

Hematologic malignancies diagnosed in the context of the mRNA COVID-19 vaccination campaign: a report of two cases

MA Zamfir, L Moraru, C Dobrea, AE Scheau, S Iacob… - Medicina, 2022 - mdpi.com
Background: During the last two years, the COVID-19 pandemic led to millions of disease-
related deaths worldwide. The efforts of the scientific community facing this global challenge …